Your browser doesn't support javascript.
loading
Combination transarterial chemoembolization and microwave ablation vs. microwave ablation monotherapy for hepatocellular carcinomas greater than 3 cm: a comparative study.
Chiang, Jason; Rajendran, Pradeep S; Hao, Frank; Sayre, James; Raman, Steven S; Lu, David S K; McWilliams, Justin P.
Afiliación
  • Chiang J; Department of Radiology, Ronald Reagan UCLA Medical Center, Los Angeles, California, USA
  • Rajendran PS; Department of Radiology, Ronald Reagan UCLA Medical Center, Los Angeles, California, USA
  • Hao F; Department of Radiology, Ronald Reagan UCLA Medical Center, Los Angeles, California, USA
  • Sayre J; Department of Radiology, Ronald Reagan UCLA Medical Center, Los Angeles, California, USA
  • Raman SS; Department of Radiology, Ronald Reagan UCLA Medical Center, Los Angeles, California, USA
  • Lu DSK; Department of Radiology, Ronald Reagan UCLA Medical Center, Los Angeles, California, USA
  • McWilliams JP; Department of Radiology, Ronald Reagan UCLA Medical Center, Los Angeles, California, USA
Diagn Interv Radiol ; 29(6): 805-812, 2023 11 07.
Article en En | MEDLINE | ID: mdl-37665139
PURPOSE: To evaluate the efficacy of combination therapy using transarterial chemoembolization with microwave ablation (MWA) therapy vs. MWA monotherapy for hepatocellular carcinomas (HCCs) >3 cm in size. METHODS: This two-arm retrospective observational study included patients with HCCs >3 cm who underwent either combination therapy (29 patients) or MWA monotherapy (35 patients) between 2014 and 2020. The treatment outcomes related to primary treatment efficacy, local tumor progression (LTP), tumor control rate, and overall survival were compared between each cohort. RESULTS: The technical success and primary efficacy were 96.56% and 100.00% in the combination therapy cohort, and 91.42% and 100.00% in the MWA cohort, respectively, over a mean follow-up period of 27.6 months. The 1- and 3-year rates of LTP-free survival were 78.57% and 69.56% in the combination therapy cohort, vs. 72.45% and 35.44% in the MWA cohort, respectively (P = 0.001). The overall progression-free survival was longer in the combination therapy cohort compared with the MWA cohort (median: 56.0 vs. 13.0 months; P = 0.017). With the incorporation of additional locoregional therapy, the overall survival rates were not significantly different, with 1- and 3-year overall survival rates of 100.00% and 88.71% in the combination therapy cohort and rates of 90.15% and 82.76% in the MWA cohort, respectively (P = 0.235). CONCLUSION: The combination therapy provided significantly longer upfront LTP-free survival in HCCs >3 cm when compared with the MWA treatment alone, albeit with similar local tumor control and overall survival rates when accounting for additional locoregional therapies.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Quimioembolización Terapéutica / Ablación por Catéter / Carcinoma Hepatocelular / Ablación por Radiofrecuencia / Neoplasias Hepáticas Tipo de estudio: Observational_studies Límite: Humans Idioma: En Revista: Diagn Interv Radiol Asunto de la revista: DIAGNOSTICO POR IMAGEM / RADIOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Turquía
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Quimioembolización Terapéutica / Ablación por Catéter / Carcinoma Hepatocelular / Ablación por Radiofrecuencia / Neoplasias Hepáticas Tipo de estudio: Observational_studies Límite: Humans Idioma: En Revista: Diagn Interv Radiol Asunto de la revista: DIAGNOSTICO POR IMAGEM / RADIOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Turquía